Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

6 Months Ended

Jun. 30, 2023

Equity Incentive Plan

Weighted-average assumptions used for the stock option grants

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
Grant date fair value			$4.23				$25.12				$4.23			$	25.12
Risk-free rate			3.9%				1.39%				3.9%				1.39%
Dividend yield			0.00%				0.00%				0.00%				0.00%
Expected life in years			6.1				5.3				6.1				5.3
Expected volatility			112%				122%				112%				122%

Schedule of stock-based compensation expense

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022
Research and development		$	48,425			$	53,309			$	96,850			$	108,510
General and administrative			82,752				208,263				165,587				365,942
		$	131,177			$	261,572			$	262,437			$	474,452

Schedule of stock option activity

		Number of Options Outstanding				Weighted- Average Exercise Price				Weighted- Average Remaining Contractual Term (in Years)
Balance at December 31, 2022			65,983			$	60.32				8.2
Options granted			36,091				4.96				9.5
Options exercised			-				-				-
Options cancelled			-				-				-
Balance at June 30, 2023			102,074			$	40.77				8.3

Options exercisable at June 30, 2023			48,300			$	64.49				7.8